These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 23192654)
41. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Alderton PM; Gross J; Green MD Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379 [TBL] [Abstract][Full Text] [Related]
42. Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Evison BJ; Mansour OC; Menta E; Phillips DR; Cutts SM Nucleic Acids Res; 2007; 35(11):3581-9. PubMed ID: 17483512 [TBL] [Abstract][Full Text] [Related]
43. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Koutinos G; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G Anticancer Res; 2002; 22(2A):815-20. PubMed ID: 12014656 [TBL] [Abstract][Full Text] [Related]
44. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. Behnia K; Boroujerdi M J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085 [TBL] [Abstract][Full Text] [Related]
45. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. Menna P; Salvatorelli E; Giampietro R; Liberi G; Teodori G; Calafiore AM; Minotti G Chem Res Toxicol; 2002 Sep; 15(9):1179-89. PubMed ID: 12230412 [TBL] [Abstract][Full Text] [Related]
46. Mitoxantrone: propensity for free radical formation and lipid peroxidation--implications for cardiotoxicity. Novak RF; Kharasch ED Invest New Drugs; 1985; 3(2):95-9. PubMed ID: 2991163 [TBL] [Abstract][Full Text] [Related]
47. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review). Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836 [TBL] [Abstract][Full Text] [Related]
48. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Doroshow JH Cancer Res; 1983 Oct; 43(10):4543-51. PubMed ID: 6309369 [TBL] [Abstract][Full Text] [Related]
49. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Callies S; de Alwis DP; Wright JG; Sandler A; Burgess M; Aarons L Cancer Chemother Pharmacol; 2003 Feb; 51(2):107-18. PubMed ID: 12647011 [TBL] [Abstract][Full Text] [Related]
50. 6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation. El-Bakly WM; Louka ML; El-Halawany AM; Schaalan MF Cancer Chemother Pharmacol; 2012 Dec; 70(6):833-41. PubMed ID: 23014738 [TBL] [Abstract][Full Text] [Related]
51. Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Evison BJ; Chiu F; Pezzoni G; Phillips DR; Cutts SM Mol Pharmacol; 2008 Jul; 74(1):184-94. PubMed ID: 18413664 [TBL] [Abstract][Full Text] [Related]
52. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701 [TBL] [Abstract][Full Text] [Related]
54. Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology. Sparano BM; Gordon G; Hall C; Iatropoulos MJ; Noble JF Cancer Treat Rep; 1982 May; 66(5):1145-58. PubMed ID: 7083217 [TBL] [Abstract][Full Text] [Related]
55. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration. Saad SY; Najjar TA; Alashari M J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649 [TBL] [Abstract][Full Text] [Related]
56. Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Beggiolin G; Crippa L; Menta E; Manzotti C; Cavalletti E; Pezzoni G; Torriani D; Randisi E; Cavagnoli R; Sala F; Giuliani FC; Spinelli S Tumori; 2001; 87(6):407-16. PubMed ID: 11989596 [TBL] [Abstract][Full Text] [Related]
57. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase. Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Yang H J Pharm Pharmacol; 2008 Dec; 60(12):1651-7. PubMed ID: 19000370 [TBL] [Abstract][Full Text] [Related]
58. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes. Menna P; Salvatorelli E; Minotti G Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277 [TBL] [Abstract][Full Text] [Related]
59. Human heart cytosolic reductases and anthracycline cardiotoxicity. Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600 [TBL] [Abstract][Full Text] [Related]